Literature DB >> 11712869

Improvement in insulin sensitivity by losartan in non-insulin-dependent diabetic (NIDDM) rats.

B Murali1, R K Goyal.   

Abstract

The present investigation was undertaken to study the effects of chronic treatment with losartan (2 mg kg(-1)/ day P.O) in neonatal non-insulin-dependent diabetes mellitus (NIDDM) rats. To induce NIDDM single-dose injection of STZ (70 mg kg(-1); i.p.) was given to 5 day old pups. The animals were weaned at 30 days and after a period of 3 months, they were checked for fasting and fed glucose levels to confirm the status of NIDDM. Losartan (2 mg kg(-1); p.o.) was administered for 6 weeks into the confirmed diabetic rats. A group of control animals were also maintained and this group received saline 5 days after birth. Fasting and fed glucose levels in NIDDM rats were significantly higher than control rats. Treatment with losartan in the NIDDM rats caused a significant decrease in insulin levels and reduction in elevated fasting and fed glucose levels. Results of the oral glucose tolerance test (OGTT) showed a significant increase in AUC(glucose)and AUC(insulin)values in NIDDM control rats. Losartan treatment significantly decreased both AUC(glucose)and AUC(insulin)values. Insulin sensitivity (K(ITT)) index of NIDDM control was significantly low as compared to Wistar control animals followed by significant increase in T(1/2)glucose value. Losartan treatment significantly reversed both K(ITT)and T(1/2)glucose value. Our data indicates that losartan increases insulin sensitivity in NIDDM rats. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11712869     DOI: 10.1006/phrs.2001.0858

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  6 in total

Review 1.  The choice of antihypertensive drugs in patients with diabetes: angiotensin II and beyond.

Authors:  Kambiz Kalantarinia; Helmy M Siragy
Journal:  Curr Diab Rep       Date:  2002-10       Impact factor: 4.810

2.  Influence of losartan on the hypoglycemic activity of glimepiride in normal and diabetic rats.

Authors:  T E G K Murthy; Manogna K Kommineni; Candasamy Mayuren
Journal:  Ther Adv Endocrinol Metab       Date:  2013-10       Impact factor: 3.565

3.  Randomized placebo-controlled trial of losartan for pediatric NAFLD.

Authors:  Miriam B Vos; Mark L Van Natta; Niviann M Blondet; Srinivasan Dasarathy; Mark Fishbein; Paula Hertel; Ajay K Jain; Saul J Karpen; Joel E Lavine; Saeed Mohammad; Laura A Miriel; Jean P Molleston; Marialena Mouzaki; Arun Sanyal; Emily P Sharkey; Jeffrey B Schwimmer; James Tonascia; Laura A Wilson; Stavra A Xanthakos
Journal:  Hepatology       Date:  2022-02-28       Impact factor: 17.298

4.  Pharmacodynamic and pharmacokinetic interaction of losartan with glimepiride-metformin combination in rats and rabbits.

Authors:  Beere Nagaraju; K V Anilkumar
Journal:  Indian J Pharmacol       Date:  2021 Nov-Dec       Impact factor: 1.200

5.  Animal models for clinical and gestational diabetes: maternal and fetal outcomes.

Authors:  Ana Ci Kiss; Paula Ho Lima; Yuri K Sinzato; Mariana Takaku; Marisa A Takeno; Marilza Vc Rudge; Débora C Damasceno
Journal:  Diabetol Metab Syndr       Date:  2009-10-19       Impact factor: 3.320

6.  Effects of Dietary Supplementation with Agaricus sylvaticus Schaeffer on Glycemia and Cholesterol after Streptozotocin-Induced Diabetes in Rats.

Authors:  Marcelo Betti Mascaro; Cristiane Miranda França; Kamilla F Esquerdo; Marx A N Lara; Nilsa S Y Wadt; Erna E Bach
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-26       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.